223 related articles for article (PubMed ID: 26484914)
21. LRP::FLAG Reduces Phosphorylated Tau Levels in Alzheimer's Disease Cell Culture Models.
Cuttler K; Bignoux MJ; Otgaar TC; Chigumba S; Ferreira E; Weiss SFT
J Alzheimers Dis; 2020; 76(2):753-768. PubMed ID: 32568204
[TBL] [Abstract][Full Text] [Related]
22. Effects of Newly Synthesized Recombinant Human Amyloid-β Complexes and Poly-Amyloid-β Fibers on Cell Apoptosis and Cognitive Decline.
Park S; Huh JW; Eom T; Na N; Lee Y; Kim JS; Kim SU; Shim I; Lee SR; Kim E
J Microbiol Biotechnol; 2017 Nov; 27(11):2044-2051. PubMed ID: 28910862
[TBL] [Abstract][Full Text] [Related]
23. Cellular prion protein as a therapeutic target in Alzheimer's disease.
Laurén J
J Alzheimers Dis; 2014; 38(2):227-44. PubMed ID: 23948943
[TBL] [Abstract][Full Text] [Related]
24. Anti-LRP/LR specific antibody IgG1-iS18 impedes adhesion and invasion of liver cancer cells.
Chetty C; Khumalo T; Da Costa Dias B; Reusch U; Knackmuss S; Little M; Weiss SF
PLoS One; 2014; 9(5):e96268. PubMed ID: 24798101
[TBL] [Abstract][Full Text] [Related]
25. Effects of Prion Protein on Aβ42 and Pyroglutamate-Modified AβpΕ3-42 Oligomerization and Toxicity.
Pagano K; Galante D; D'Arrigo C; Corsaro A; Nizzari M; Florio T; Molinari H; Tomaselli S; Ragona L
Mol Neurobiol; 2019 Mar; 56(3):1957-1971. PubMed ID: 29981054
[TBL] [Abstract][Full Text] [Related]
26. Cytotoxicity of prion protein peptide (PrP106-126) differs in mechanism from the cytotoxic activity of the Alzheimer's disease amyloid peptide, A beta 25-35.
Hope J; Shearman MS; Baxter HC; Chong A; Kelly SM; Price NC
Neurodegeneration; 1996 Mar; 5(1):1-11. PubMed ID: 8731376
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of cellular prion protein (PrP(C)) prevents cognitive dysfunction and apoptotic neuronal cell death induced by amyloid-β (Aβ₁₋₄₀) administration in mice.
Rial D; Piermartiri TC; Duarte FS; Tasca CI; Walz R; Prediger RD
Neuroscience; 2012 Jul; 215():79-89. PubMed ID: 22537845
[TBL] [Abstract][Full Text] [Related]
28. Amyloid-beta-induced neurotoxicity is reduced by inhibition of glycogen synthase kinase-3.
Koh SH; Noh MY; Kim SH
Brain Res; 2008 Jan; 1188():254-62. PubMed ID: 18031715
[TBL] [Abstract][Full Text] [Related]
29. Amyloid β cytotoxicity is enhanced or reduced depending on formation of amyloid β oligomeric forms.
Shahnawaz M; Bilkis T; Park IS
Biotechnol Lett; 2021 Jan; 43(1):165-175. PubMed ID: 33025333
[TBL] [Abstract][Full Text] [Related]
30. An Aβ42 variant that inhibits intra- and extracellular amyloid aggregation and enhances cell viability.
Oren O; Banerjee V; Taube R; Papo N
Biochem J; 2018 Oct; 475(19):3087-3103. PubMed ID: 30213841
[TBL] [Abstract][Full Text] [Related]
31. Anti-LRP/LR specific antibody IgG1-iS18 significantly impedes adhesion and invasion in early and late stage colorectal carcinoma cells.
Vania L; Chetty CJ; Ferreira E; Weiss SFT
Mol Med; 2016 Oct; 22():664-673. PubMed ID: 27611822
[TBL] [Abstract][Full Text] [Related]
32. The Anti-Prion Antibody 15B3 Detects Toxic Amyloid-β Oligomers.
Stravalaci M; Tapella L; Beeg M; Rossi A; Joshi P; Pizzi E; Mazzanti M; Balducci C; Forloni G; Biasini E; Salmona M; Diomede L; Chiesa R; Gobbi M
J Alzheimers Dis; 2016 Jul; 53(4):1485-97. PubMed ID: 27392850
[TBL] [Abstract][Full Text] [Related]
33. High molecular mass assemblies of amyloid-β oligomers bind prion protein in patients with Alzheimer's disease.
Dohler F; Sepulveda-Falla D; Krasemann S; Altmeppen H; Schlüter H; Hildebrand D; Zerr I; Matschke J; Glatzel M
Brain; 2014 Mar; 137(Pt 3):873-86. PubMed ID: 24519981
[TBL] [Abstract][Full Text] [Related]
34. The chemerin receptor CMKLR1 is a functional receptor for amyloid-β peptide.
Peng L; Yu Y; Liu J; Li S; He H; Cheng N; Ye RD
J Alzheimers Dis; 2015; 43(1):227-42. PubMed ID: 25079809
[TBL] [Abstract][Full Text] [Related]
35. Adhesion and Invasion of Breast and Oesophageal Cancer Cells Are Impeded by Anti-LRP/LR-Specific Antibody IgG1-iS18.
Khumalo T; Reusch U; Knackmuss S; Little M; Veale RB; Weiss SF
PLoS One; 2013; 8(6):e66297. PubMed ID: 23823499
[TBL] [Abstract][Full Text] [Related]
36. The Mode of Action of an Anti-Oligomeric Amyloid β-Protein Antibody Affects its Protective Efficacy.
Zhang Y; Huai Y; Zhang X; Song C; Cai J; Zhang Y
Neurotox Res; 2019 Feb; 35(2):304-317. PubMed ID: 30229545
[TBL] [Abstract][Full Text] [Related]
37. Influence of LRP-1 and apolipoprotein E on amyloid-β uptake and toxicity to cerebrovascular smooth muscle cells.
Ruzali WA; Kehoe PG; Love S
J Alzheimers Dis; 2013; 33(1):95-110. PubMed ID: 22914594
[TBL] [Abstract][Full Text] [Related]
38. Laminin inhibits both Abeta40 and Abeta42 fibril formation but does not affect Abeta40 or Abeta42-induced cytotoxicity in PC12 cells.
Monji A; Tashiro K; Yoshida I; Kaname H; Hayashi Y; Matsuda K; Tashiro N
Neurosci Lett; 1999 May; 266(2):85-8. PubMed ID: 10353333
[TBL] [Abstract][Full Text] [Related]
39. Rebamipide reduces amyloid-β 1-42 (Aβ42) production and ameliorates Aβ43-lowered cell viability in cultured SH-SY5Y human neuroblastoma cells.
Fukui K; Yachi K; Yoshida H; Tanji K; Matsumiya T; Hayakari R; Tsuruga K; Tanaka H; Imaizumi T
Neurosci Res; 2017 Nov; 124():40-50. PubMed ID: 28587858
[TBL] [Abstract][Full Text] [Related]
40. Subcellular localization of prion proteins and the 37 kDa/67 kDa laminin receptor fused to fluorescent proteins.
Nikles D; Vana K; Gauczynski S; Knetsch H; Ludewigs H; Weiss S
Biochim Biophys Acta; 2008 May; 1782(5):335-40. PubMed ID: 18339329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
